Brequinar sodium
- PMID: 7492488
- DOI: 10.1007/BF00867685
Brequinar sodium
Abstract
Brequinar sodium is one of a new group of immunosuppressive drugs currently being developed for the prevention of organ graft rejection. The preclinical and clinical characterization of brequinar sodium has clearly demonstrated that this drug is a compound with highly effective immunosuppressive activity that is the result of its interference with pyrimidine biosynthesis and the disruption in cell proliferation. The antiproliferative activity of the drug influences both T and B cell immune function, thereby providing the potential for the use of this compound in combination with other immunosuppressive agents for more specific and effective prevention of allograft and xenograft rejection. Experimental studies with brequinar and cyclosporin or FK 506 have shown that the use of these agents in combination provides a synergistic effect for the prevention of graft rejection, and studies are now in progress to evaluate the application of this drug in clinical transplantation.
Similar articles
-
Prevention of vascularized allograft and xenograft rejection in rodents by brequinar sodium.Transplant Proc. 1993 Jun;25(3 Suppl 2):23-8. Transplant Proc. 1993. PMID: 8516938 Review.
-
The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat.Transplantation. 1992 Feb;53(2):303-8. doi: 10.1097/00007890-199202010-00009. Transplantation. 1992. PMID: 1531394
-
The development of Brequinar as an immunosuppressive drug for transplantation.Immunol Rev. 1993 Dec;136:51-70. doi: 10.1111/j.1600-065x.1993.tb00654.x. Immunol Rev. 1993. PMID: 8132203 Review.
-
The synergism of brequinar sodium and cyclosporine used in combination to prevent cardiac allograft rejection in the rat.Transplantation. 1993 Sep;56(3):667-72. doi: 10.1097/00007890-199309000-00032. Transplantation. 1993. PMID: 8212165
-
Combination therapy with Brequinar sodium and cyclosporine synergistically prolongs hamster-to-rat cardia xenograft survival.J Heart Lung Transplant. 1994 May-Jun;13(3):489-97. J Heart Lung Transplant. 1994. PMID: 8061026
Cited by
-
Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.Cell. 2016 Sep 22;167(1):171-186.e15. doi: 10.1016/j.cell.2016.08.057. Epub 2016 Sep 15. Cell. 2016. PMID: 27641501 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical